- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06328465
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases (fREEDOM)
March 21, 2024 updated by: European Institute of Oncology
The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment.
The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Breast cancer is the second most common cancer in the world and the most common cancer among women.
In these patients, it is not the primary tumor, but its distant metastases that are the main cause of death.
Follow-up may vary depending on the hospital or doctor, but the data available in the literature do not show an advantage in terms of survival or quality of life in patients subjected to intensive follow-up.
However, the information that physicians have comes from past studies limited by the presence of bias regarding patient characteristics, therapies, follow-up intervals and tests used.
In light of the better understanding of biology, breast cancer is no longer considered a single disease, but it is classified into at least four different molecular subtypes, based on the immunohistochemical classification: Luminal A-like, Luminal B-like, HER2 positive and Triple Negative.
Nowadays it is known that not only the stage of diagnosis, but also the biology of the disease influences the risk of recurrence and death.
Furthermore, a growing number of trials show that different biological subtypes differ in terms of time to relapse and disease pattern of metastatic spread (in particular, site of first relapse).
These observations lead to the hypothesis that different types and different frequencies of follow-up strategies should vary depending on the biology of breast cancer.
Furthermore, with improved management and the availability of new effective treatments, patients with oligometastatic disease treated with an aggressive multidisciplinary approach may be amenable to curative treatment.
Based on this hypothesis, an early diagnosis of metastatic disease could lead to the identification of patients with low disease burden who can still be treated with curative intent.
DWB-MRI is emerging as a promising tool for the detection and therapy monitoring of metastases in different tumor types and could be an important tool for the early detection of breast cancer metastases.
Study Type
Interventional
Enrollment (Estimated)
145
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Monica Iorfida, MD
- Phone Number: +390257489970
- Email: monica.iorfida@ieo.it
Study Locations
-
-
-
Milan, Italy, 20141
- Recruiting
- European Institute of Oncology
-
Contact:
- Mara Negri
- Phone Number: +390257489536
- Email: mara.negri@ieo.it
-
Contact:
- Monica Iorfida, MD
- Phone Number: +390257489970
- Email: monica.iorfida@ieo.it
-
Principal Investigator:
- Monica Iorfida, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pre or post-menopausal patient with histologically confirmed invasive breast cancer stage II - III HER2 + or TN operated breast carcinoma or patients underwent neoadjuvant treatment (included cT4d) with residual disease at definitive surgery
- No evidence of distant metastases at baseline perioperative radiological staging (DWB-MRI, total body Computed Tomography (CT) or Positron Emission Tomography (PET/CT) must be performed +/- 1 month from surgery)
- No relevant comorbidities
- Eastern Cooperative Oncology Group (ECOG) performance status 0
- Geographically accessible for follow up
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Absolute contraindications that exclude the execution of the MRI investigation, regardless of the clinical indication
- Relative contraindications that include situations in which the innocuousness of the examination is not documented with certainty that therefore do not recommend the execution, except for serious indications related to the patient's clinical need
- Older age (>75 years)
- Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix
- Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DWB-MRI
Surveillance with diffusion whole body MRI
|
Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
5-year overall survival
Time Frame: 5 years
|
Number of alive patients at 5 years (considering deaths from any cause)
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival of patients underwent local treatment
Time Frame: 5 years
|
Number of patients undergoing local treatment (surgery or other localized technique) who are alive at 5 years (considering deaths from any cause)
|
5 years
|
Breast cancer specific survival
Time Frame: 5 years
|
Number of alive patients at 5 years (considering only deaths related to breast cancer)
|
5 years
|
Safety of local treatment
Time Frame: 48 months
|
Number of serious adverse event related to local treatment received
|
48 months
|
Anxiety assessment
Time Frame: 48 months
|
Collection of Hamilton Anxiety Rating Scale questionnaire (minimum value: 0, maximum value: 4 - higher scores mean a worse outcome)
|
48 months
|
Health state assessment
Time Frame: 48 months
|
Collection of 12-Item Short Form Survey (SF-12) questionnaire (minimum value: 0, maximum value: 6 - higher scores mean a better outcome)
|
48 months
|
Ability to Cope With Trauma assessment
Time Frame: 48 months
|
Collection of Perceived Ability to Cope With Trauma (PACT) questionnaire (minimum value: 0, maximum value: 7 - higher scores mean a better outcome)
|
48 months
|
Personality assessment
Time Frame: 48 months
|
Collection of Big Five Personality Inventory (BFI-10) questionnaire (minimum value: 0, maximum value: 5 - higher scores mean a greater agreement with the statement)
|
48 months
|
Acceptability and perception of DWB-MRI
Time Frame: 48 months
|
Collection of Acceptance Questionnaire (minimum value: 0, maximum value: 5 - higher scores mean a worse outcome)
|
48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Monica Iorfida, MD, European Institute of Oncology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2019
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
March 13, 2024
First Submitted That Met QC Criteria
March 21, 2024
First Posted (Actual)
March 25, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IEO 1108
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on Diffusion whole body MRI
-
Vall d'Hebron Institute of OncologyProstate Cancer Foundation; Instituto de Salud Carlos III; Hospital Vall d'Hebron and other collaboratorsRecruitingProstate Cancer MetastaticSpain
-
CHU de ReimsUnknownNeuroendocrine Tumors With Metastasis
-
Universitaire Ziekenhuizen KU LeuvenCompletedGastrointestinal Stromal TumorsBelgium
-
Universitaire Ziekenhuizen KU LeuvenUnknownNon-invasive | Gastro-intestinal Tumor | Accurate Staging | Whole-body Diffusion Weighted MRIBelgium
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Completed
-
University of UtahRecruitingSmoldering Multiple MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
Laval UniversityRecruitingPancreas Adenocarcinoma | Pancreas Cancer, Duct Cell Adenocarcinoma | Peritoneal Carcinomatosis | Peritoneal MetastasesCanada
-
Laval UniversityCiusss de L'Est de l'Île de MontréalRecruitingColorectal Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Appendix Cancer | Appendix NeoplasmCanada
-
Guy's and St Thomas' NHS Foundation TrustNot yet recruiting